Oncopeptides AB (publ) (ONCO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Oncopeptide's third quarter earnings call for 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Sophia Hagas and CFO Henrik Bergentoft. Please go ahead. Hi everyone and welcome to the presentation of Oncopeptides report for the third quarter of 2025. My name is Sofia Heggis and I am the CEO of Oncopeptides. As we have increased our shareholder base the last quarter I wish to welcome old as well as new shareholders to this earnings course. This is our standard disclaimer. As usually I'm joined by our CFO Henrik Bergentoft and together we present our financial and operational performance for the third quarter, which is concluding that we are still on track towards becoming a profitable company by the end of 2026. The third quarter was a strategically important period for local peptides, as we knew we would have to demonstrate resilience in execution given the vacation period. Net sales reached 20.2 million sets representing a 174% increase year over year and marking our fourth consecutive quarter over quarter growth. In July, we delivered an all-time high which was followed by another all-time high in September. In between, we saw a seasonal slowdown typical during the European vacation period. And all in all, we saw a quarter of growth, which is a stronger result than the same period in 2024. So even though we are still sensitive to seasonal effects, this is a sign of how we have strengthened our position and advanced our launch. Our cash position at the end of the period was 147.9 million SEK, reflecting the successful completion of a rights...